Dosing & Dose Modifications

DOSING

Dosing of MYLOTARG in newly diagnosed pediatric patients is based on body surface area1
  • The recommended dose of MYLOTARG in pediatric patients 1 month and older is:
    • 3 mg/m2 for patients with body surface area (BSA) greater than or equal to 0.6 m2
    • 0.1 mg/kg for patients with BSA less than 0.6 m2
  • For Induction 1, MYLOTARG is given once on Day 6 in combination with standard chemotherapy. No MYLOTARG is given in the second induction cycle 
  • For Intensification 2, MYLOTARG is given once on Day 7 in combination with standard chemotherapy. No MYLOTARG is given in the first or third intensification cycles 
  • Consider the risks and potential benefits before giving MYLOTARG during Intensification 2 
Before starting MYLOTARG
  • Premedicate pediatric patients 1 month and older with acetaminophen 15 mg/kg (maximum of 650 mg) and diphenhydramine 1 mg/kg (maximum of 50 mg) 1 hour prior to MYLOTARG dosing, and 1 mg/kg methylprednisolone orally or intravenously within 30 minutes prior to infusion of MYLOTARG 
  • Additional doses of acetaminophen and diphenhydramine may be administered every 4 hours after the initial pretreatment dose 
  • Repeat with the same dose of methylprednisolone or an equivalent corticosteroid for any sign of an infusion reaction, such as fever, chills, hypotension, or dyspnea during the infusion or within 4 hours afterwards 
Cytoreduction
  • For patients with hyperleukocytosis (leukocyte count ≥30 Gi/L), cytoreduction is recommended prior to administration of MYLOTARG
  • Use appropriate measures to prevent tumor lysis syndrome
REFERENCE
1. MYLOTARG Prescribing Information. New York, NY: Pfizer Inc.

DOSE MODIFICATIONS

Dose modifications for toxicities1
  • Monitor blood counts frequently through resolution of cytopenias 
  • Monitor blood counts and chemistries at least 3 times per week through recovery from treatment-related toxicities 
  • Management of some adverse reactions may require dose interruptions or permanent discontinuation of MYLOTARG 
REFERENCE
1. MYLOTARG Prescribing Information. New York, NY: Pfizer Inc.